British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care University of Cambridge United Kingdom.
Heart and Lung Research Institute University of Cambridge United Kingdom.
J Am Heart Assoc. 2023 Aug;12(15):e029296. doi: 10.1161/JAHA.122.029296. Epub 2023 Jul 25.
Background The aim of this study was to provide quantitative evidence of the use of polygenic risk scores for systematically identifying individuals for invitation for full formal cardiovascular disease (CVD) risk assessment. Methods and Results A total of 108 685 participants aged 40 to 69 years, with measured biomarkers, linked primary care records, and genetic data in UK Biobank were used for model derivation and population health modeling. Prioritization tools using age, polygenic risk scores for coronary artery disease and stroke, and conventional risk factors for CVD available within longitudinal primary care records were derived using sex-specific Cox models. We modeled the implications of initiating guideline-recommended statin therapy after prioritizing individuals for invitation to a formal CVD risk assessment. If primary care records were used to prioritize individuals for formal risk assessment using age- and sex-specific thresholds corresponding to 5% false-negative rates, then the numbers of men and women needed to be screened to prevent 1 CVD event are 149 and 280, respectively. In contrast, adding polygenic risk scores to both prioritization and formal assessments, and selecting thresholds to capture the same number of events, resulted in a number needed to screen of 116 for men and 180 for women. Conclusions Using both polygenic risk scores and primary care records to prioritize individuals at highest risk of a CVD event for a formal CVD risk assessment can efficiently prioritize those who need interventions the most than using primary care records alone. This could lead to better allocation of resources by reducing the number of risk assessments in primary care while still preventing the same number of CVD events.
本研究旨在提供多基因风险评分用于系统识别个体以进行全正式心血管疾病(CVD)风险评估的定量证据。
使用 UK Biobank 中年龄在 40 至 69 岁之间、具有测量生物标志物、关联的初级保健记录和遗传数据的 108685 名参与者进行模型推导和人群健康建模。使用纵向初级保健记录中可用的年龄、冠心病和中风多基因风险评分以及 CVD 的传统危险因素的优先排序工具,使用性别特异性 Cox 模型进行推导。我们模拟了在优先考虑邀请进行正式 CVD 风险评估后启动指南推荐的他汀类药物治疗的影响。如果使用初级保健记录根据与 5%假阴性率相对应的年龄和性别特异性阈值对个体进行正式风险评估进行优先级排序,则预防 1 例 CVD 事件所需的男性和女性人数分别为 149 和 280。相比之下,将多基因风险评分添加到优先级排序和正式评估中,并选择捕获相同数量事件的阈值,导致男性和女性的筛查人数分别为 116 和 180。
使用多基因风险评分和初级保健记录共同优先考虑 CVD 事件风险最高的个体进行正式 CVD 风险评估,可以比仅使用初级保健记录更有效地优先考虑最需要干预的个体。这可以通过减少初级保健中的风险评估数量来更好地分配资源,同时仍然预防相同数量的 CVD 事件。